SCHEMBL14763562

SCHEMBL14763562

CC(O)C(O)NC(CS)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
THRB P10828 1/20 0.50
ALOX15 P16050 1/20 0.50
NFKB1 P19838 1/20 0.50
PTGS2 P35354 1/20 0.50
THPO P40225 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
FOLH1 Q04609 3/20 0.39
NAALAD2 Q9Y3Q0 2/20 0.35
ENPEP Q07075 2/20 0.35
ALDH1A1 P00352 2/20 0.35
TP53 P04637 1/20 0.35
MME P08473 4/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14763564 1.00 ACE (0.50) ACEKDM4EMAPTTHRBALOX15
SCHEMBL23552453 0.83 KDM4E (0.54) ACEKDM4EMAPTTHRBALOX15
SCHEMBL313275 0.83 KDM4E (0.54) ACEKDM4EMAPTTHRBALOX15
SCHEMBL1058214 0.80 KDM4E (0.56) ACEKDM4EMAPTTHRBALOX15
SCHEMBL25761663 0.80 KDM4E (0.56) ACEKDM4EMAPTTHRBALOX15
SCHEMBL1058215 0.80 KDM4E (0.56) ACEKDM4EMAPTTHRBALOX15
SCHEMBL28854052 0.80 KDM4E (0.56) ACEKDM4EMAPTTHRBALOX15
SCHEMBL2910735 0.79 SMN1; SMN2 (0.39) SMN1; SMN2FOLH1NAALAD2MME
SCHEMBL2910743 0.79 SMN1; SMN2 (0.39) SMN1; SMN2FOLH1NAALAD2MME
SCHEMBL2910739 0.79 SMN1; SMN2 (0.39) SMN1; SMN2FOLH1NAALAD2MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11458212-B2 Molecular imaging of cancer cells in vivo H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-10-04 US disclosed
US-20200164093-A1 Molecular Imaging of Cancer Cells In Vivo H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2020-05-28 US disclosed
US-10406248-B2 Molecular imaging of cancer cells in vivo H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2019-09-10 US disclosed
US-20140161725-A1 Molecular Imaging of Cancer Cells In Vivo ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2014-06-12 US disclosed
WO-2013036543-A2 MOLECULAR IMAGING OF CANCER CELLS IN VIVO H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2013-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140161725-A1 Molecular Imaging of Cancer Cells In Vivo MKI67, ANXA4, ANXA3 ACE 4618/4885KDM4E 4702/4885MAPT 3135/4885
US-11458212-B2 Molecular imaging of cancer cells in vivo MKI67, ANXA4, ANXA3 ACE 4618/4885KDM4E 4702/4885MAPT 3135/4885
US-10406248-B2 Molecular imaging of cancer cells in vivo MKI67, ANXA4, ANXA3 ACE 4618/4885KDM4E 4702/4885MAPT 3135/4885
US-20200164093-A1 Molecular Imaging of Cancer Cells In Vivo MKI67, ANXA4, ANXA3 ACE 4618/4885KDM4E 4702/4885MAPT 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.